🧬 SinoBioData Academic Portal
Open AccessDOI: 10.3724/abbs.2025068Original Research

Intracellular acetyl phosphate modulates Escherichia coli pyruvate metabolism

🇨🇳 Original Chinese Title: Intracellular acetyl phosphate modulates Escherichia coli pyruvate metabolism

Ling Zhang¹,Hongmei Shi¹,Zixiang Liu¹,Jing Gu¹,Jiaoyu Deng¹

Wuhan Institute of Virology, Chinese Academy of Sciences

Read Executive PreviewQuick FAQ
Intracellular acetyl phosphate modulates Escherichia coli pyruvate metabolism
Graphical Abstract / Figure
Published In
Acta Biochimica et Biophysica Sinica
Published:2025Edition:Vol. 57, Issue 9 • pp. 1539-1547Citation:Ling Zhang et al. (2025), Acta Biochimica et Biophysica Sinica
Impact FactorPremier Chinese Biomedical Journal indexed in SinoBioData: Acta Biochimica et Biophysica Sinica (生物化学与生物物理学报).
Sponsored Research Partner

Key Takeaways & Executive Findings

  • • Acetyl phosphate (AcP) directly acetylates and phosphorylates E. coli pyruvate dehydrogenase (AceE), modulating its enzymatic activity. • CobB deacetylase reverses AcP-mediated acetylation of AceE, highlighting a reversible regulatory mechanism. • Deletion of ackA or pta alters AceE acetylation and activity, leading to pyruvate accumulation and changes in pyruvate metabolism gene expression. • This study establishes a novel link between AcP-mediated protein acetylation, pyruvate dehydrogenase activity, and pyruvate metabolism in E. coli.
Sponsored Research Highlight

Abstract

Lysine acetylation has been shown to be an abundant and vital post-translational modification (PTM) that utilizes acetyl phosphate (AcP) as one of the acetyl group donors in bacteria. The pyruvate dehydrogenase (PDH) complex catalyzes the conversion from pyruvate to acetyl coenzyme A (acetyl-CoA). Thus far, the connection between lysine acetylation and pyruvate metabolism has not been thoroughly investigated. In this study, we show that AcP could acetylate Escherichia coli pyruvate dehydrogenase (AceE) in vitro and in vivo, which could be reversed by protein lysine deacetylase (CobB). In vitro treatment of AceE with AcP also causes increased phosphorylation of the protein, whereas deleting ackA does not affect the phosphorylation of the protein. As a result, in vitro treatment of AceE by AcP leads to decreased enzymatic activity. In contrast, deleting ackA leads to increased acetylation and enzymatic activity of AceE, and deleting pta results in the decreased acetylation and enzymatic activity of AceE. As expected, deleting pta in E. coli causes pyruvate accumulation. Although deleting ackA also causes pyruvate accumulation, decreased expression of the two genes involved in pyruvate metabolism (ldhA and poxB) is observed in the mutant, indicating that AcP could affect pyruvate metabolism by other routes in addition to modulating the AceE activity. Thus, our results demonstrate that intracellular AcP could modulate pyruvate metabolism in E. coli. For the first time, a linkage between AcP-mediated protein lysine acetylation, pyruvate dehydrogenase activity, and pyruvate metabolism is established.

1. Introduction

Protein lysine acetylation is an abundant and vital post-translational modification across all domains of life that is involved in central metabolism, transcription regulation, protein synthesis, cell morphology, the cell cycle, signal pathway regulation, the stress response, and pathogenic microorganism infection regulation [1,2]. It occurs through two different routes. The first route is enzymatic, relying on lysine acetyltransferases (KATs), such as YfiQ (patZ), RimI, YiaC, YjaB, and PhnO [1], to transfer an acetyl group from acetyl-CoA to Nε-lysine residues [2]. The second route is non-enzymatic, in which acetyl phosphate donates its acetyl group to the ε-amino group of lysine residues [3‒5]. Protein lysine acetylation is reversible, and acetylated lysine can be enzymatically deacetylated by lysine deacetylases (KDACs). In Escherichia coli, the Sirtuin family protein CobB can deacetylate both enzymatically acetylated and non-enzymatically acetylated lysines [6].

Acetyl phosphate (AcP) was first found to be a precursor of acetic acid during fermentation, which is involved in acetate activation for its metabolic functions [7]. Phosphate acetyltransferase (Pta) catalyzes the conversion between acetyl-CoA and AcP, and acetate kinase (AckA) catalyzes the conversion between AcP and acetate. Both reactions are readily reversible. Cells lacking AckA can convert acetyl-CoA to AcP but cannot degrade AcP to acetate, leading to elevated AcP levels [8]. In contrast, cells lacking both Pta and AckA cannot synthesize AcP from either AcCoA or acetate, which completely abolishes AcP production. Previous studies showed that AcP could be a phosphoryl and an acetyl group donor for protein post-translational modifications (PTMs) [9]. In E. coli, acetylation of K243 by AcP inhibits the oriC binding ability of DNA [10]. In Salmonella, acetylation of K102 inhibits the activity of PhoP [11]. In Mycobacterium tuberculosis, AcP-dependent acetylation of the cyclic AMP receptor protein affects the virulence of the bacterium [12]. In Actinobacteria, AcP-dependent modification networks regulate c-di-AMP homeostasis [13]. In Baccilus subtili, AcP-mediated lysine acetylation modulates the activity of acetyl-CoA synthetase [14]. However, Bacillus subtilis DegU can be phosphorylated by AcP in the absence of DegS [15]. AcP has also been identified in vivo as an alternative source of CiaR phosphorylation in the absence of CiaH [16]. In Staphylococcus aureus, AcP-mediated phosphorylation inhibits the enzyme activity of SrtA [17]. However, the physiological roles of AcP-dependent acetylation or phosphorylation remain largely unknown.

Pyruvate is located at a significant metabolic node, which links carbohydrate catabolism to energy generation and biosynthesis and represents a major switch point between respiratory and fermentative metabolism [18]. The pyruvate dehydrogenase (PDH) complex converts pyruvate to acetyl coenzyme A (acetyl-CoA). The E. coli PDH complex has three components: pyruvate dehydrogenase (E1, AceE), dehydrolipoate acyltransferase (E2, AceF), and dihydrolipoate dehydrogenase (E3, LPD) [18]. AceE catalyzes the decarboxylation of pyruvate, a key step in the pathway.

SinoBioData Interactive Document Reader
Page 1–5 of Preview
100%
Download Full PDF

Loading authentic research manuscript (Pages 1–5)...

Sponsored Research Partner
Cite This Research Paper
Ling Zhang, Hongmei Shi, Zixiang Liu, Jing Gu, Jiaoyu Deng (2026). Intracellular acetyl phosphate modulates Escherichia coli pyruvate metabolism. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2025068
SinoBioData Academic & Legal Disclaimer

Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.

Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.

Frequently Asked Questions

What is the role of acetyl phosphate in E. coli pyruvate metabolism?

Acetyl phosphate (AcP) modulates pyruvate metabolism by acetylating and phosphorylating pyruvate dehydrogenase (AceE), thereby affecting its enzymatic activity. This regulation influences pyruvate accumulation and the expression of genes involved in pyruvate metabolism.

How does AcP affect AceE activity?

In vitro treatment of AceE with AcP leads to increased phosphorylation and decreased enzymatic activity. Conversely, deleting ackA (which elevates AcP levels) increases acetylation and enzymatic activity, while deleting pta (which reduces AcP) decreases acetylation and activity.

What is the significance of CobB in this context?

CobB is a protein lysine deacetylase that can reverse AcP-mediated acetylation of AceE, providing a reversible regulatory mechanism for pyruvate metabolism.

What are the implications of this study for understanding bacterial metabolism?

This study establishes a novel link between AcP-mediated protein acetylation, pyruvate dehydrogenase activity, and pyruvate metabolism, highlighting AcP as a key metabolic regulator beyond its role as an intermediate in acetate metabolism.

How does deleting ackA or pta affect pyruvate accumulation?

Deleting either ackA or pta leads to pyruvate accumulation in E. coli. However, the mechanisms differ: ackA deletion increases AceE acetylation and activity, while pta deletion decreases acetylation and activity, and also affects the expression of ldhA and poxB genes.

Recommended Scientific Literature & Research Partners

Related Technical Papers & Translations

Research Paper
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis

Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis

Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.

Read Abstract & PDF
Research Paper
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials

Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials

Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.

Read Abstract & PDF
Research Paper
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.

Read Abstract & PDF